TABLE 1.
Direct target genes and functions of miRNAs
| miRNA | Direct target gene | Function | Category | Ref |
|---|---|---|---|---|
| miR‐9 | BRCA1 | Sensitization to cisplatin | Anti‐ | 42 |
| miR‐21‐3p | SOCS4, SOCS5 | Remodeling of macrophages to TAMs | Pro‐ | 27 |
| miR‐21‐5p | STAT3 | Treg/Th17 imbalance | Pro‐ | 28 |
| miR‐21 | APAF1 | Enhancement of resistance to paclitaxel | Pro‐ | 49 |
| miR‐21 | unknown | Promotion of angiogenesis | Pro‐ | 55 |
| miR‐29a‐3p | STAT3 | Treg/Th17 imbalance | Pro‐ | 28 |
| miR‐92a | DKK1 | Maintenance of stemness | Pro‐ | 20 |
| miR‐99a‐5p | FN1, VTN | Promotion of cancer cell invasion by remodeling peritoneal mesothelial cells | Pro‐ | 30 |
| miR‐141 | p38α | Promotion of cell proliferation/sensitization to paclitaxel | Pro‐/anti‐ | 12 |
| miR‐141 | CXCL12β | Maintenance of immunocompetence | Anti‐ | 26 |
| miR‐141 | unknown | Sensitization to paclitaxel/enhancement of resistance to carboplatin | Anti‐/pro‐ | 39 |
| miR‐141 | KEAP1 | Enhancement of resistance to cisplatin | Pro‐ | 41 |
| miR‐141‐3p | unknown | Promotion of angiogenesis | Pro‐ | 54 |
| miR‐124 | SPHK1 | Dedifferentiation of CAFs to normal fibroblasts | Anti‐ | 25 |
| miR‐125b‐5p | SOCS4 | Remodeling of macrophages to TAMs | Pro‐ | 27 |
| miR‐125b | ERBB3 | Inhibition of angiogenesis | Anti‐ | 51 |
| miR‐126‐5p | DKK3, AXIN1, BACH1, NFAT5 | Enhancement of resistance to cisplatin | Pro‐ | 46 |
| miR‐181a | SMAD7 | Promotion of cellular survival, migration, invasion, and drug resistance | Pro‐ | 18 |
| miR‐181d‐5p | SOCS5 | Remodeling of macrophages to TAMs | Pro‐ | 27 |
| miR‐182 | BRCA1 | Sensitization to radiation and PARP inhibitor | Anti‐ | 60 |
| miR‐182 | unknown | Promotion of cell proliferation, invasion, and metastasis | Pro‐ | 61 |
| miR‐193a‐3p | GRB7 | Suppression of cell proliferation, migration, and invasion | Anti‐ | 22 |
| miR‐195‐5p | PSAT1 | Sensitization to cisplatin and inhibition of angiogenesis | Anti‐ | 47 |
| miR‐199a | ERBB2 | Inhibition of angiogenesis | Anti‐ | 51 |
| miR‐200a | p38α | Promotion of cell proliferation/sensitization to paclitaxel | Pro‐/anti‐ | 12 |
| miR‐200a | CXCL12β | Maintenance of immunocompetence | Anti‐ | 26 |
| miR‐200a | Unknown | Sensitization to paclitaxel/enhancement of resistance to carboplatin | Anti‐/pro‐ | 39 |
| miR‐200b | Unknown | Promotion of cell proliferation | Pro‐ | 17 |
| miR‐200c | NRP1 | Sensitization to PARP inhibitor | Anti‐ | 63 |
| miR‐200 family | ZEB1/2 | Maintenance of epithelial state | Anti‐ | 14 |
| miR‐200 family | IL8, CXCL1 | Inhibition of angiogenesis | Anti‐ | 56 |
| miR‐205 | Unknown | Promotion of angiogenesis | Pro‐ | 53 |
| miR‐216b | PARP1 | Sensitization to cisplatin | Anti‐ | 45 |
| miR‐223 | PTEN | Enhancement of resistance to cisplatin | Pro‐ | 50 |
| miR‐484 | VAGFB, VEGFR2 | Inhibition of angiogenesis | Anti‐ | 57 |
| miR‐506 | CDK4/6 | Suppression of cell proliferation | Anti‐ | 21 |
| miR‐506 | RAD51 | Sensitization to cisplatin and PARP inhibitor | Anti‐ | 43 |
| miR‐509‐3p | RAD51, HMGA2 | Sensitization to cisplatin and PARP inhibitor | Anti‐ | 44 |
| miR‐551b‐3p | STAT3 | Resistance to apoptosis and promotion of survival and proliferation | Pro‐ | 19 |
| miR‐591 | ZEB1 | Enhancement of resistance to paclitaxel | Pro‐ | 40 |
| miR‐622 | KU70, KU80 | Enhancement of resistance to cisplatin and PARP inhibitor | Pro‐ | 62 |
| miR‐1246 | CAV1 | Enhancement of resistance to paclitaxel | Pro‐ | 48 |
Abbreviations: anti‐, anti‐oncogenic; CAFs, cancer‐associated fibroblasts; pro‐, pro‐oncogenic; Ref, references; TAMs, tumor‐associated macrophages.